Effects of sacubitril/valsartan in the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) according to background therapy

Circulation: Heart Failure

Volumn 9, Issue 9, 2016, Pages

  Okumura, Naoki ^a   Jhund, Pardeep S ^a   Gong, Jianjian ^b   Lefkowitz, Martin P ^b   Rizkala, Adel R ^b   Rouleau, Jean L ^c   Shi, Victor C ^b   Swedberg, Karl ^d,e   Zile, Michael R ^f   Solomon, Scott D ^g   Packer, Milton ^h   Mcmurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

^c MONTREAL HEART INSTITUTE   (Canada)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

heart failure; neprilysin; sacubitril valsartan

Indexed keywords

BISOPROLOL; CARVEDILOL; DIGITALIS GLYCOSIDE; DIGOXIN; DIURETIC AGENT; ENALAPRIL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; MINERALOCORTICOID ANTAGONIST; NEBIVOLOL; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOTONIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TETRAZOLE DERIVATIVE;

ADULT; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; CARDIOVERSION; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DEVICES; MORTALITY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOTONIC AGENTS; DEFIBRILLATORS, IMPLANTABLE; DIURETICS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ELECTRIC COUNTERSHOCK; ENALAPRIL; HEART FAILURE; HUMANS; MYOCARDIAL REVASCULARIZATION; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84988667458     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.116.003212     Document Type: Article

References (20)

1. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Committees and Investigators Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013 15 1062 1073. doi: 10.1093/eurjhf/hft052
2. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014 371 993 1004. doi: 10.1056/NEJMoa1409077
3. Moe GW, Ezekowitz JA, O?Meara E, Lepage S, Howlett JG, Fremes S, Al-Hesayen A, Heckman GA, Abrams H, Ducharme A, Estrella-Holder E, Grzeslo A, Harkness K, Koshman SL, McDonald M, McKelvie R, Rajda M, Rao V, Swiggum E, Virani S, Zieroth S, Arnold JM, Ashton T, D?Astous M, Chan M, De S, Dorian P, Giannetti N, Haddad H, Isaac DL, Kouz S, Leblanc MH, Liu P, Ross HJ, Sussex B, White M, Canadian Cardiovascular Society The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: anemia, biomarkers, and recent therapeutic trial implications. Can J Cardiol 2015 31 3 16. doi: 10.1016/j.cjca.2014.10.022
4. Braunwald E, The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. J Am Coll Cardiol 2015 65 1029 1041. doi: 10.1016/j.jacc.2015.01.033
5. The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987 316 1429 35
6. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991 325 293 302
7. Digitalis Investigation Group The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997 336 525 533
8. CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999 353 9 13
9. MERIT-HF Study Group Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999 353 2001 2007
10. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL, Carvedilol Prospective Randomized Cumulative Survival Study Group Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001 344 1651 1658. doi: 10.1056/NEJM200105313442201
11. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 341 709 717. doi: 10.1056/NEJM199909023411001
12. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHASIS-HF Study Group Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011 364 11 21. doi: 10.1056/NEJMoa1009492
13. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH, Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005 352 225 237. doi: 10.1056/NEJMoa043399
14. Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, O'Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau JL, STICH Investigators Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med 2011 364 1607 1616. doi: 10.1056/NEJMoa1100356
15. Brookes ST, Whitely E, Egger M, Smith GD, Mulheran PA, Peters TJ, Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. J Clin Epidemiol 2004 57 229 236. doi: 10.1016/j.jclinepi.2003.08.009
16. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM, Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 2007 357 2189 2194. doi: 10.1056/NEJMsr077003
17. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N, Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996 94 2807 2816
18. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, McDonagh T, Sechtem U, Bonet LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, Ponikowski P, Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology; ESC Committee for Practice Guidelines ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012 14 803 869. doi: 10.1093/eurjhf/hfs105
19. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013 128 1810 1852. doi: 10.1161/CIR.0b013e31829e8807
20. Kristensen SL, Martinez F, Jhund PS, Arango JL, Bělohlávek J, Boytsov S, Cabrera W, Gomez E, Hagège AA, Huang J, Kiatchoosakun S, Kim K-S, Mendoza I, Senni M, Squire IB, Vinereanu D, Wong RC, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJ V, Geographic variations in the PARADIGM-HF heart failure trial [published online ahead of print June 28, 2016]. Eur Heart J. doi 10.1093/eurheartj/ehw226